Lantheus Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
LNTH$101.62+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
The following consolidated financial statements of Lantheus Holdings, Inc. are filed as part of this Annual Report on Form 10-K under Part II, Item 8. Financial Statements and Supplementary Data:
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | 82 |
| Consolidated Balance Sheets | 84 |
| Consolidated Statements of Operations | 85 |
| Consolidated Statements of Comprehensive Income | 86 |
| Consolidated Statements of Changes in Stockholders’ Equity | 87 |
| Consolidated Statements of Cash Flows | 88 |
| Notes to Consolidated Financial Statements | 90 |
(a)(2) Schedules
All schedules are omitted because they are not applicable, not required, or because the required information is included in the consolidated financial statements or notes thereto.
(a)(3) Exhibits
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibits | Form | FileNumber | Exhibit | Filing Date |
| 2.1††# | Agreement and Plan of Merger, dated as of January 27, 2025, by and among Lantheus Medical Imaging, Inc., Project Hazel Merger Sub, Inc., Evergreen Theragnostics, Inc., Shareholder Representative Services LLC and, for purposes of Section 11.2 only, Lantheus Holdings, Inc. | 8-K | 001-36569 | 2.1 | January 28, 2025 |
| 3.1 | Amended and Restated Certificate of Incorporation of Lantheus Holdings, Inc. | 8-K | 001-36569 | 3.1 | April 27, 2018 |
| 3.2 | Amended and Restated Bylaws of Lantheus Holdings, Inc. | 8-K | 001-36569 | 3.2 | May 5, 2025 |
| 4.1 | Common Stock Certificate. | 8-K | 001-36569 | 4.1 | June 30, 2015 |
| 4.2* | Description of Registrant’s Securities | ||||
| 4.3 | Indenture, dated as of December 8, 2022, between Lantheus Holdings, Inc., as Issuer, Lantheus Medical Imaging, Inc., as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee | 8-K | 001-36569 | 4.1 | December 8, 2022 |
| 10.1+ | 2015 Equity Incentive Plan of Lantheus Holdings, Inc. | S-8 | 333-205211 | 4.1 | June 26, 2015 |
| 10.2+ | Form of 2015 Restricted Stock Agreement of Lantheus Holdings, Inc. | S-1 | 333-196998 | 10.38 | June 24, 2015 |
| 10.3+ | Form of 2015 Option Award Agreement of Lantheus Holdings, Inc. | S-1 | 333-196998 | 10.39 | June 24, 2015 |
| 10.4+ | Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan. | 8-K | 001-36569 | 10.1 | April 28, 2016 |
| 10.5+ | Second Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 8-K | 001-36569 | 10.1 | April 28, 2017 |
| 10.6+ | Form of Severance Agreement (executives with existing employment agreements). | 10-K | 001-36569 | 10.70 | February 20, 2019 |
| 10.7+ | Form of Severance Agreement (executives without existing employment agreements). | 10-K | 001-36569 | 10.71 | February 20, 2019 |
| 10.8+ | Third Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 10-Q | 001-36569 | 10.1 | April 30, 2019 |
| 10.9+ | Fourth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 10-Q | 001-36569 | 10.2 | July 25, 2019 |
| 10.10+ | Lantheus Holdings, Inc. 2005 Stock Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2005 Stock Incentive Plan). | S-8 | 333-239491 | 4.4 | June 26, 2020 |
| 10.11+ | Lantheus Holdings, Inc. 2018 Performance Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan). | S-8 | 333-239491 | 4.5 | June 26, 2020 |
| 10.12 | Lease, dated December 31, 2015, between the Registrant and WTC TOWER 1 LLC. | 8-K | 000-23143 | 10.46 (21) | January 5, 2016 |
| 10.13+ | Fifth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 8-K | 001-36569 | 10.1 | April 29, 2021 |
| 10.14†† | Manufacturing and Supply Agreement, effective as of February 23, 2022, by and between Lantheus Medical Imaging, Inc. and Jubilant HollisterStier LLC. | 10-Q | 001-36569 | 10.1 | April 29, 2022 |
| 10.15 | Form of Restricted Stock Unit Award Agreement (Employee Time-Based Vesting) of Lantheus Holdings, Inc. | 10-Q | 001-36569 | 10.2 | April 29, 2022 |
| 10.16 | Form of Restricted Stock Unit Award Agreement (Relative Total Shareholder Return Performance-Based Vesting) of Lantheus Holdings, Inc. | 10-Q | 001-36569 | 10.3 | April 29, 2022 |
| 10.17 | Form of Stock Option Award Agreement (Time Vesting) of Lantheus Holdings, Inc. | 10-Q | 001-36569 | 10.4 | April 29, 2022 |
| 10.18 | Sixth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 8-K | 001-36569 | 10.1 | May 2, 2022 |
| 10.19†† | License and Collaboration Agreement, dated as of November 11, 2022, by and between Point Biopharma, Inc., and Lantheus Two, LLC. | 8-K | 000-36569 | 10.1 | November 14, 2022 |
| 10.20 | Credit Agreement dated as of December 2, 2022 by and among Citizens Bank, N.A., as administrative agent and collateral agent, each of the lenders from time to time party thereto, Lantheus Medical Imaging, Inc., as borrower, and Lantheus Holdings, Inc. | 8-K | 001-36569 | 10.1 | December 5, 2022 |
| 10.21+ | Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan | 8-K | 001-36569 | 10.1 | May 1, 2023 |
| 10.22†† | Office Lease by and between Lantheus Medical and 201 Burlington Road Owner, LLC dated February 14, 2022 (the “Lease”); as amended by the First Amendment To Lease dated May 4, 2023 | 10-Q | 001-36569 | 10.1 | August 3, 2023 |
| 10.23 | First Amendment to License and Collaboration Agreement (PNT-2002), dated as of January 31, 2024, by and between POINT Biopharma, Inc. and Lantheus Two, LLC and Lantheus Medical Imaging, Inc. | 10-Q | 001-36569 | 10.1 | May 2, 2024 |
| 10.24 | Seventh Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 8-K | 001-36569 | 10.1 | April 29, 2024 |
| 10.25†† | Second Amendment to Lease dated as of October 3, 2024 | 10-K | 001-36569 | 10.32 | February 26, 2025 |
| 10.26 | Eighth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 10-Q | 001-36569 | 10.1 | November 6, 2024 |
| 10.27 | First Amendment to Credit Agreement, dated December 19, 2024, among Lantheus Medical Imaging Inc., Lantheus Holdings, Inc., the lenders and other parties party thereto and Citizens Bank N.A., as administrative and collateral agent | 8-K | 001-36569 | 10.1 | December 23, 2024 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibits | Form | FileNumber | Exhibit | Filing Date |
| 10.28+ | Form of Indemnification Agreement | 10-K | 001-36569 | 10.35 | February 26, 2025 |
| 10.29+ | Nonqualified Deferred Compensation Plan | 10-K | 001-36569 | 10.36 | February 26, 2025 |
| 10.30†† | Sale and Purchase Agreement, dated as of January 12, 2025, by and among Life Medical Group Limited and Life Healthcare Group Holdings Limited and Lantheus Radiopharmaceuticals UK Limited and Lantheus Medical Imaging Inc. | 10-K | 001-36569 | 10.37 | February 26, 2025 |
| 10.31 | Third Amendment to Lease dated as of February 14, 2025, by and between Lantheus Medical and 201 Burlington Road Owner, LLC | 10-Q | 001-36569 | 10.1 | May 7, 2025 |
| 10.32+ | Ninth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan | 10-Q | 001-36569 | 10.1 | August 6, 2025 |
| 10.33# | Deed of Amendment and Restatement Relating to a Sale and Purchase Agreement entered into July 21, 2025, by and among Life Medical Group Limited and Life Healthcare Group Holdings Limited and Lantheus | 10-Q | 001-36569 | 10.1 | November 6, 2025 |
| 10.34+* | Consulting Agreement, effective as of November 6, 2025, by and between Brian Markison and Lantheus Medical Imaging Inc. | ||||
| 10.35+* | Retirement and Separation Agreement, effective as of November 6, 2025, by and between Brian Markison and Lantheus Medical Imaging Inc. | ||||
| 10.36+* | Employment Agreement, effective November 7, 2025, by and between Lantheus Medical Imaging, Inc. and Mary Anne Heino | ||||
| 19.1 | Policy on Insider Trading and Communications with the Public | 10-K | 001-36569 | 19.1 | February 26, 2025 |
| 21.1* | Subsidiaries of Lantheus Holdings, Inc. | ||||
| 23.1* | Consent of Independent Registered Public Accounting Firm. | ||||
| 24.1* | Power of Attorney (included as part of the signature page hereto). | ||||
| 31.1* | Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | ||||
| 31.2* | Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | ||||
| 32.1** | Certification pursuant to 18 U.S.C. Section 1350. | ||||
| 97.1 | Amended and Restated Executive Compensation Clawback Policy | 10-K | 001-36569 | 97.1 | February 26, 2025 |
| 101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document With Embedded Linkbase Documents | ||||
| 104* | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed herewith.
** Furnished herewith.
†† Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
- Indicates management contract or compensatory plan or arrangement.
† Confidential treatment requested as to certain portions, which portions have been filed separately with the Securities and Exchange Commission.
Pursuant to Item 601(b)(2)(ii) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company customarily and actually treats such omitted information as private or confidential and because such omitted information is not material.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.